1-9 of 9
Kevin J. Freise
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

Chewei Anderson Chang, Ethan Emberley, Aloma L. D'Souza, Weilong Zhao, Cormac Cosgrove, Karen Parrish, Diya Mitra, Elmer Payson, Anatol Oleksijew, Paul Ellis, Luis Rodriguez, Ryan Duggan, Cara Hrusch, Loren Lasko, Wissam Assaily, Pingping Zheng, Wei Liu, Axel Hernandez, Jr., Kimberley McCarthy, Zhaomei Zhang, Geunbae Rha, Zhensheng Cao, Yingchun Li, Olivia Perng, Jos Campbell, Gloria Zhang, Tyler Curran, Milan Bruncko, Christopher C. Marvin, Adrian Hobson, Michael McPherson, Tamar Uziel, Marybeth A. Pysz, Xi Zhao, Alex Bankovich, Joel Hayflick, Michael McDevitt, Kevin J. Freise, Susan Morgan-Lappe, James W. Purcell
Journal: Blood
Blood (2024) 144 (7): 757–770.
https://doi.org/10.1182/blood.2024023849
Published: 2024
Includes: Supplemental data
Journal Articles

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug Conjugate Composed of a CD19 Antibody Linked to a Potent Proprietary Glucocorticoid Receptor Modulator, in Patients with Relapsed or Refractory B-Cell Malignancies

Moshe Levy, Carl Gustafson, James Purcell, Kevin J. Freise, Wissam Assaily, Deanna Brackman, William R. Henner, Michael McDevitt, John Kuruvilla
Journal: Blood
Blood (2022) 140 (Supplement 1): 3746–3747.
https://doi.org/10.1182/blood-2022-166809
Published: 2022
Journal Articles

A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Orlando F. Bueno, Ben Buelow, Kevin J. Freise, Susan Yue, Rajvineeth Kumar Pothacamury, Akshanth R. Polepally, Ravi Vij
Journal: Blood
Blood (2021) 138 (Supplement 1): 900.
https://doi.org/10.1182/blood-2021-150757
Published: 2021
Journal Articles

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Luciano J Costa, MD PhD, Edward A. Stadtmauer, MD FACP, Gareth Morgan, MD, Gregory Monohan, MD, Tibor Kovacsovics, MD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Mehrdad Mobasher, MD MPH, Kevin J. Freise, PhD, Jeremy A. Ross, PhD, John Pesko, PhD, Wijith Munasinghe, PhD, Saketh Gudipati, MD, Sarah Mudd, PhD, Orlando Bueno, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 303.
https://doi.org/10.1182/blood-2018-99-117026
Published: 2018
Journal Articles

Phase 1/2 Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Venetoclax in Japanese Subjects with Chronic Lymphocytic Leukemia

Kiyohiko Hatake, MD PhD, Kazuhito Yamamoto, MDPhD, Noriko Fukuhara, MD PhD, Shigeru Kusumoto, MD, Koji Izutsu, MD, PhD, Ilseung Choi, MD, Hirokazu Nagai, MD PhD, Hideyuki Honda, BS, Junjiro Saeki, MS, Andrew W. Roberts, MS, Paulo Maciag, MD PhD, Suresh Agarwal, MS, PhD RPh, Ahmed Hamed Salem, PhD, Kevin J. Freise, PhD, Tsukasa Kiriyama, PharmD, BSc, Kensei Tobinai, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5352.
https://doi.org/10.1182/blood.V130.Suppl_1.5352.5352
Published: 2017
Journal Articles

Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies

Sathej Gopalakrishnan, PhD, Brenda Chyla, PhD, Sven Mensing, PhD, Rajeev Menon, PhD, Rod Humerickhouse, MD PhD, Walid Awni, PhD, Ahmed Hamed Salem, PhD, Kevin J. Freise, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4318.
https://doi.org/10.1182/blood.V130.Suppl_1.4318.4318
Published: 2017
Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3131.
https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131
Published: 2017
Journal Articles

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Clinical Trials & Observations
Philippe Moreau, Asher Chanan-Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, Shaji Kumar, Cyrille Touzeau, Elizabeth A. Punnoose, Jaclyn Cordero, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Kevin J. Freise, Joel D. Leverson, Sari Heitner Enschede, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo, Simon J. Harrison
Journal: Blood
Blood (2017) 130 (22): 2392–2400.
https://doi.org/10.1182/blood-2017-06-788323
Published: 2017
Includes: Supplemental data
Journal Articles

Relationship Between Short-Term Response Rates and Long-Term Survival in Acute Myeloid Leukemia and Relapsed or Refractory Multiple Myeloma

Naveen Mangal, MS, Ahmed H. Salem, Rajeev Menon, PhD, Kevin J. Freise, PhD
Journal: Blood
Blood (2016) 128 (22): 5128.
https://doi.org/10.1182/blood.V128.22.5128.5128
Published: 2016